Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma,

Background Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell

Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is

Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker

Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered

Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise

Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma. David Allmond, John McEvoy and Laura Maher will join the company in the